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Despite ovarian cancer (OC) represents the leading cause of death in gynecology, however, current 
understanding of the molecular machinery governing initiation, development and recurrence of the tumor is still 
limited. Particularly, lack of specific biomarkers defining the complex states of OC limits effective diagnosis and 
prognosis and, subsequently, hinders appropriate therapy strategies for OC patients. MicroRNA (miR) are small 
non-coding, regulatory RNA molecules which have critical functions in tumor biology, and which have been 
functionally grouped into tumor suppressive and tumor promoting miR. miR-1 has been described operating as 
a tumor suppressor which attenuates proliferation and progression in divers solid cancer entities. Currently, 
there are no data available concerning miR-1 functionality in progression of OC, particularly, in regard to its 
potential as a biomarker for OC diagnosis and treatment. Therefore, the present study examined miR-1 
expression levels in established OC cell lines as well as in tissue samples from primary and relapsed OC patients 
to get a first understanding of putative miR-1 properties in OC progression. Notably, we found miR-1 in OC cell 
lines was linked to higher cell growth rates. Moreover, analysis of patient samples revealed miR-1 levels in 
relapsed tumors appeared being up-regulated compared to primary tumors. The findings of our preliminary 
study (1) may suggest a novel role of miR-1 in OC as a promotor of cancer progression or (2) exhibit a 
dysregulation of miR-1 functions by a so far unknown disruption of miR-1 regulatory cascades. 
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Introduction 
Ovarian cancer (OC) is the leading cause of death among 
all gynecological malignancies 
[1]
. The advanced stage at the
time of diagnosis is defined by a lack of specific symptoms 
and explained by the absence of appropriate screening tests. 
Despite achievements in both surgical treatment and the 
development of new drugs the 5-year survival rate remains 
very low 
[2]
. For these reasons, there is an urgent need to find
new predictive and prognostic factors for OC diagnosis and 
prognosis as well as new targets for novel treatment options. 
Even though OC represents the most lethal cancer in 
gynecological oncology, unfortunately, very little is known 
about the molecular machinery governing tumor 
development and progression. MicroRNA (miR) are small 
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non-coding RNA molecules that play a pivotal role in control 
of gene expression at the post-transcriptional level 
[3]
. The 
molecular mode of action is characterized by the specific 
binding to mRNA followed by (1) an increased degradation 
of the target mRNA or (2) an enhanced repression of 
translation 
[4]
. Current studies have identified dysregulated 
miR expression pattern in various malignancies and, thus, 
pointed to miR being exceedingly involved in tumor 
initiation and progression 
[5, 6]
. Numerous miR have been 
shown to display tumor suppressor properties while others 
harbor oncogenic activities (oncomirs) 
[7]
. Up to now, 
approximately 40 miR species have been identified and 
partially characterized with regard to their characteristics in 
OC progression; to our best knowledge, nothing is known 
about miR-1 functionality in OC. Formerly, miR-1 was 
specified to be specific for skeletal and heart muscle cells 
with nearly undetectable levels in other tissues 
[8]
. However, 
recent studies showed miR-1 linked to central mechanisms in 
tumor biology, e.g. suppression of tumor growth, 
epithelial-mesenchymal transition, and cell motility 
[9–11]
, and 
from these properties it follows that miR-1 belongs to the 
miR group of tumor suppressors. 
Therefore, the present work investigated for the first time 
expression levels of miR-1 in OC to get a first understanding 
of putative miR-1 properties in OC cells. Particularly, this 
preliminary study focused on miR-1 expression rates in five 
established OC cell lines and 21 tumor tissue samples to 
obtain first hints on the regulatory role of miR-1 in OC 
progression. 
Materials and Methods 
Cell Culture 
The human OC cell lines OVCAR-3 and SKOV-3 - both 
received from Cell Lines Service (Eppelheim, Germany) - 
were propagated in RPMI 1640 medium (Biochrom, Berlin, 
Germany) containing 10% fetal calf serum (Biochrom), 
0.125% gentamicin (Ratiopharm, Ulm, Germany) and 0.1% 
insulin (Novo Nordisk, Mainz, Germany), and DMEM/F12 
(Life Technologies, Darmstadt, Germany) supplemented 
with 5% fetal calf serum and 0.125% gentamicin, 
respectively. The OC cell lines UWB1.289, TOV-112D, and 
TOV-21G - all purchased from the American Type Culture 
Collection (Manassas, VA, USA) - were propagated in RPMI 
(Biochrom)/MEGM (Lonza, Basel, Switzerland) 1:1 media 
mixture containing 3% fetal calf serum and 0.065% 
gentamicin (UWB 1.289) and MCDB105 (tebu-Bio, 
Offenbach, Germany)/Medium 199 (Biochrom) mixture 
containing 15% fetal calf serum and 0.125% gentamicin 
(TOV-112D, TOV-21G). Cells were passaged twice per 
week in a humidified atmosphere at 37°C and 5% CO2. 
Proliferation Assay 
Cellular growth of OC cells was examined by cell 
counting utilizing a CASY Cell Counter and Analyzer Model 
TT (Roche Applied Science, Mannheim, Germany). 
Therefore, adherent cells were detached by trypsin treatment, 
suspended in CASYton (Roche Applied Science) as 1:100 
dilution and 400 µl of cell suspension were analysed with 3 
replicates. Measurement was performed using a capillary of 
150 µm in diameter and cell line specific gate settings to 
discriminate between living , dead cells, and cellular debris: 
9.00 µm/15.75 µm (OVCAR-3), 7.00 µm/15.15 µm 
(SKOV-3), 7.15 µm/15.65 µm (UWB1.289), 5.25 µm/10.15 
µm (TOV-21G), and 6.15 µm/11.00 µm (TOV-112D). 
Patients Samples 
This study was approved by the Ethics Committee of the 
University Medicine Greifswald (registration no. III SV 
05/04) and all patients signed informed consent forms. All 
samples and related clinical data were obtained from the 
Department of Gynecology and Obstetrics, Universitiy 
Medicine Greifswald. The control group consisted of women 
with no history of malignancy. In order to obtain detailed and 
complete data about the histo-pathological features of the 
tumores and the surgical treatment, the IMO (intraoperative 
mapping of ovarian cancer) documentation system was used 
[12]
. 
RNA Preparation and cDNA Synthesis 
For detection of miR-1 expression in OC cell lines 
OVCAR-3, SKOV-3, UWB1.289, TOV-112D, and 
TOV-21G, cells were grown in a 6-well cell culture plate to 
80% confluency, and total RNA was prepared using 
peqGOLD Trifast Reagent (Peqlab Biotechnology, Erlangen, 
Germany) according to the manufacturer's instructions. For 
total RNA isolation from OC tumor tissue 50 - 150 g tissue 
were applied to the NucleoSpin RNA/Protein Kit 
(Macherey-Nagel, Düren, Germany) according to the 
supplier’s instructions. Subsequently, RNA concentration 
was determined utilizing a Nanodrop 2000c UV/vis 
spectrophotometer (Peqlab Biotechnology) and RNA was 
stored at -80°C. 
For reverse transcription 100 ng of total RNA were used 
with the Superscript II Reverse Transcriptase (Life 
Technologies) according to the protocol of Chen et al. 
[13]
. 
Stem-loop primers for reverse transcription were designed as 
follows: miR-1 stem-loop: 5'-GTCGTATCCAGTGCAGGG 
TCCGAGGTATTCGCACTGGATACGACATACAT-3'; U6 
stem-loop: 5'-GTCATCCTTGCGCAGG-3'. 
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Table 1. Patient characteristics, pathology results, and miR-1 levels 
patient  Rel. miR-1 expression 
No. age FIGO pathology  primary relapse 
1 53 IV serous papillary  0.29 ± 0.10 - 
2 61 IIIc serous papillary  7.48 ± 3.47 - 
3 65 IIIc serous papillary  0.78 ± 0.94 - 
4 71 IIIc endometroid  0.15 ± 0.06 - 
5 72 IV serous papillary  0.24 ± 0.01 - 
6 76 IIIc serous papillary  0.06 ± 0.05 - 
7 70 IIIc serous papillary  0.37 ± 0.31 - 
8 65 IIIb serous papillary  0.34 ± 0.32 - 
9 58 IIIc serous papillary  0.18 ± 0.01 0.29 ± 0.06 
10 55 IV serous papillary  0.11 ± 0.00 0.36 ± 0.16 
11 48 IIIc serous papillary  0.05 ± 0.02 2.81 ± 0.44 
12 35 IIIc serous papillary  0.03 ± 0.01 0.17 ± 0.03 
13 45 III serous papillary  - 0.03 ± 0.03 
14 72 IV serous papillary  - 1.29 ± 0.03 
15 76 IIIc serous papillary  - 0.98 ± 0.00 
16 70 III serous papillary  - 1.07 ± 1.13 
17 65 IIIc serous papillary  - 0.17 ± 0.15 
 
Quantification of miR-1 by Polymerase Chain Reaction 
Quantification of miR-1 was performed with the SensiMix 
SYBR hi-ROX Kit (Bioline, Luckenwalde, Germany) on a 
CFX96 Real-Time System (Bio-Rad, München, Germany) 
with the CFX Manager software (Bio-Rad). The sequences 
of the PCR primers were as follows: miR-1 forward: 
5'-GCCCGCTGGAATGTAAAGAAGTATG-3'; miR-1 
reverse: 5'-GTGCAGGGTCCGAGGT-3'; U6 forward: 
5'-CGCTTCGGCAGCACATATAC-3'; U6 reverse: 
5'-AGGGGCCATGCTAATCTTCT-3'. The cycling 
parameters were one denaturation cycle at 95°C for 5 min 
and 45 amplification cycles at 95°C for 10 sec, 60°C for 20 
sec, and 72°C for 10 sec, followed by a melt curve analysis. 
For quantification, miR-1 signals were standardized to U6 
RNA as reference. 
Statistics 
Data were evaluated using the graphics and statistics 
software program Graph Pad Prism (version 5.01) and 
expressed in column or box plot presentations. Statistical 
comparisons were performed using the unpaired Student’s t 
test with results of p ≤ 0.05 were given as significant. 
Results 
Highly variable miR-1 expression rates in OC cell lines 
In this study we aimed at analysing expression levels of 
miR-1 in OC cell lines as well as in OC tissue samples. To 
proof whether miR-1 is expressed in cells from OC origin, 
we tempted to compare intracellular miR-1 concentrations in 
the established OC cell lines SKOV-3, OVCAR-3, 
UWB1.289, TOV-21G, and TOV-112D. Basal miR-1 signals 
were detectable in all of these cell lines with relative 
concentrations of 0.03 ± 0.05 (SKOV-3), 0.08 ± 0.04 
(OVCAR-3), 0.24 ± 0.41 (UWB1.289), 0.39 ± 0.48 
(TOV-21G:), and 1.10 ± 0.32 (TOV-112D; Fig. 1). 
Comparison of miR-1 expression levels with SK-OV-3 (set 
to 1.0) revealed expression values of 2.5-fold (OVCAR-3), 
8.1-fold (UWB1.289), 12.8-fold (TOV-21G), and 36.7-fold 
(TOV-112D), demonstrating highly mutable expression rates 
of miR-1. However, due to variance only the mean miR-1 
expression in TOV-112D was statistically significant 
compared to the other cell lines. 
Cell growth kinetics of OC cell lines correlate with miR-1 
expression levels 
To determine whether different levels of miR-1 expression 
define differences in cellular growth of the OC cell lines, we 
counted living cells of incubated OC cells at indicated time 
points over a period of 144 h (Figure 2). Notably, cellular 
proliferation was found being linked to the basal expression 
of miR-1: TOV-112D (24 h: 2.1 ± 0.7, 48 h: 5.8 ± 0.1, 72 h: 
12.2 ± 0.9, 96 h: 20.3 ± 0.8, 120 h: 32.0 ± 6.8, 144 h: 42.2 ± 
5.4); TOV-21G (24 h: 2.7 ± 0.6, 48 h: 5.3 ± 0.0, 72 h: 11.9 ± 
2.1, 96 h: 24.6 ± 5.4, 120 h: 38.3 ± 7.7, 144 h: 51.3 ± 10.7); 
UWB1.289 (24 h: 3.0 ± 0.6, 48 h: 4.7 ± 1.1, 72 h: 6.9 ± 1.8, 
96 h: 8.6 ± 0.3, 120 h: 13.8 ± 3.4, 144 h: 19.7 ± 4.2); 
SKOV-3 (24 h: 2.6 ± 1.6, 48 h: 4.3 ± 0.2, 72 h: 7.9 ± 0.8, 96 
h: 13.0 ± 1.8, 120 h: 15.7 ± 2.1, 144 h: 20.4 ± 0.5); 
OVCAR-3 (24 h: 3.0 ± 1.3, 48 h: 4.3 ± 0.1, 72 h: 7.2 ± 0.3, 
96 h: 10.9 ± 0.4, 120 h: 13.2 ± 2.2, 144 h: 15.9 ± 3.1). The 
higher the level of miR-1 in OC cells, the higher the rates of 
cell growth were detected (TOV-112D, TOV-21G), whereas 
moderate and low miR-1 expression were related to 
diminished cell proliferation (UWB1.289, SKOV-3, 
OVCAR-3). 
miR-1 expression in tissue samples from healthy donors 
and primary OC turmors varies compared to secondary 
tumor tissues from OC patients 
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While differential expression of miR-1 was detectable in 
OC cell lines, tumor samples were included in this 
preliminary study to perform a miR-1 expression profiling. A 
total of 21 tumor samples from OC patients were compared 
to ovarian tissue samples from 4 non-malignant donors 
obtained from the Department of Gynecology and Obstetrics 
at the University Medicine Greifswald. OC patients were 
caucasians with an average age at the time of surgery of 59.7 
and FIGO stages from III to IV (Table 1). OC samples were 
sub-classified in primary tumor tissue (n=12; patient no. 1 to 
12) and samples from relapsed tumors (n=8; patient no. 9 to 
17). Noteworthy, four samples of both groups were obtained 
from the same four individuals (patient no. 9 to 12). 
Box plot analysis of intracellular miR-1 concentration 
graphically depicted no significant differences in miR-1 
expression in healthy tissue and primary tumor samples 
(Figure 3A). In contrast, miR-1 expression in relapsed 
tumors appeared being upregulated compared to primary 
tumors. Notably, a subset analysis of patients 9 to 12 
demonstrated that there was a distinct rise in miR-1 
expression comparing primary and relapsed tumor tissues in 
individual patients (Figure 3B). 
Discussion 
OC is a highly heterogenous and severe malignant disease, 
for which no satisfactory treatment options are yet available. 
Due to the fact that molecular research should provide 
much-needed information about novel predictive and 
prognistic factors, we analyzed the expression of miR-1 in 
OC cell lines and tumor samples. The panel of probed OC 
cell lines demonstrated highly variable miR-1 concentrations 
reaching a basal level up to 36.7-fold higher in TOV-112D 
cells than in the low-expression cell line SKOV-3. miR-1 
was strongly expressed in TOV-112D and TOV-21G cells, 
and moderate expressed in UWB1.289 cells, whereas 
SKOV-3 and OVCAR-3 cells weakly expressed miR-1. 
Recent studies stated miR-1 functionality in solid 
malignancies as tumor-suppressive. Molecular analysis in 
bladder cancer 
[14, 15]
, prostate cancer 
[9, 10, 16]
, colon cancer 
[11, 
17]
, and renal cell carcinoma 
[18]
 strongly interrelated cellular 
miR-1 properties with mechanisms of growth inhibition and 
general anti-oncogenic cell response. On the contrary and 
rather surprisingly, miR-1 levels in OC cell lines as 
determined in this study were linked to in vitro growth 
characteristics of the cells: high level miR-1 cell lines 
(TOV-21G, TOV-112D), however, demonstrated clearly 
higher proliferation rates than OC cells bearing lower levels 
of miR-1 (UWB1.289, SKOV-3, OVCAR-3). 
In order to shed further light on the putative role of miR-1 
in OC, we assessed miR-1 expression levels in primary and 
relapsed states of OC. A comparison of ovarian miR-1 status 
of healthy women with primary OC tumors disclosed none or 
even low differences in expression. Interestingly, miR-1 
levels analyzed in the subsets of primary and relapsed 
tumors, however, revealed elevated values and a higher 
median of miR-1 concentration in relapsed tumors. 
Admittedly, variations as well as few numbers of samples in 
this preliminary study prohibited statistical analysis of the 
box plot presentation. Further analysis of primary and 
relapsed tumors from individuals underscored the previous 
findings: all samples of the four patients showed an increase 
of miR-1 expression from primary to relapsed tumor 
samples. 
Figure 1. miR-1 analysis in established OC cell lines revealed 
highly variable expression levels. Relative miR-1 levels 
normalized to intracellular U6 RNA concentrations ranged from 0.03 
± 0.05 (1.0-fold; SKOV-3) to 1.10 ± 0.32 (36.7-fold; TOV-112D). 
Columns were calculated as the mean ± SD of relative miR-1 
concentrations with given p values determined by Student's t test. 
 
Figure 2. Growth characteristics of OC cell lines correlated 
with intracellular miR-1 concentrations. Cellular growth was 
determined at indicated time points utilizing a CASY Cell Counter 
and Analyzer Model TT. High level miR-1 cell lines (TOV-112D, 
TOV-21G) demonstrated clearly higher rates of proliferation 
compared to moderate and low miR-1 expressing cells (UWB1.289, 
SKOV-3, OVCAR-3). Results are expressed as the mean ± SD of 
105 cells. 
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In conclusion, a clear decrease of miR-1 in malignant 







, and lung 
[20]
, has not been 
detected in OC. Furthermore, combining miR-1 in OC cell 
lines was linked to higher proliferation, together with 
potentially up-regulated miR-1 levels in relapsed and 
therefore highly oncogenic OC, makes miR-1 role as tumor 
suppressor rather implausible. This may suggest that (1) 
miR-1 may be able to govern OC cell growth contradicting 
the tumor suppressor properties observed in other cancer 
types, or (2) miR-1 tumor suppressor functions may be 
dysregulated in OC cells by the disruption of 
miR-1-depending signaling cascades and/or effector 
molecules. Although miR-1 functionality in OC oncogenesis 
remains unclear, however, elevated levels of miR-1 during 
tumor progression may serve as a promising marker for OC 
recurrence. 
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Figure 3. Analysis of primary and relapsed OC tumor samples demonstrated no 
attenuation of miR-1 compared to healthy tissue and tended to result in increased 
levels of miR-1 in relapsed tumors. Relative miR-1 levels normalized to intracellular 
U6 RNA concentrations of healthy (n=4) ovarian samples, and primary (n=12) as well as 
relapsed (n=9) OC tumor samples showed no reduction in miR-1 expression in 
malignant tissues. Comparison of primary and relapsed tumor samples indicated a 
weak increase of miR-1 within the subset of relapsed tissues. Results are expressed as 
box plot presentation; variations and few numbers of samples prohibited statistical 
analysis (A). Analysis of four patients from which primary as well as relapsed samples 
were available indicated elevated levels of miR-1 in all of the relapsed state of OC. 
Columns were calculated as the mean ± SD of relative miR-1 concentrations with given 
p values determined by Student's t test (B). 
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